Hepatect Cp (Human Hepatitis B Immunoglobulin)

Hepatect Cp is indicated for specific clinical situations where passive immunity against hepatitis B virus is required.

• Post‑exposure prophylaxis to prevent hepatitis B infection after known or suspected exposure.
• Prevention of hepatitis B recurrence in recipients of liver transplants.
• Supplementation of hepatitis B vaccine in individuals with inadequate immune response.
• Use in patients with chronic liver disease who are at high risk of hepatitis B infection.
• Administration to newborns of hepatitis B‑positive mothers when active vaccination is delayed.

The safety profile of Hepatect Cp reflects the typical reactions associated with immunoglobulin preparations administered intravenously.

Common

• Mild fever or chills during or shortly after infusion.
• Headache or fatigue.
• Localized pain, erythema, or swelling at the injection site.
• Nausea or mild gastrointestinal discomfort.

Serious

• Severe allergic reactions, including anaphylaxis or serum sickness.
• Acute hypotension or cardiovascular collapse.
• Renal dysfunction or hemolysis.

Clinicians should consider several precautions when prescribing Hepatect Cp to ensure safe administration.

• Assess patient history for prior hypersensitivity to blood products or immunoglobulins.
• Monitor vital signs during infusion, especially during the first administration.
• Adjust infusion rate if signs of intolerance such as fever or chills appear.
• Use caution in patients with renal impairment or a history of hemolytic disorders.
• Avoid use in individuals with known IgA deficiency who have anti‑IgA antibodies.
• Consider pregnancy status; the safety profile in pregnancy is not well established.
• Ensure proper aseptic technique to prevent contamination of the injectable solution.

Hepatect Cp may interact with other medications or substances that affect immune response or cardiovascular stability.

Avoid

• Concurrent administration of other immunoglobulin products without appropriate spacing.
• Simultaneous infusion of blood products that could increase the risk of volume overload.

Use with caution

• Concurrent use of antihistamines or corticosteroids, which may mask infusion reactions.
• Administration alongside nephrotoxic agents in patients with pre‑existing renal dysfunction.
• Co‑administration with vaccines, as passive antibodies may interfere with active immunization response.